Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...
JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.
Dividend investors entering July 2026 have a rare setup: Three of the market’s most reliable income stocks all delivered beat-and-raise first-quarter reports, all hiked their payouts in the past 12 months and all three are riding meaningful momentum into the back half of the year. The thesis is simple. When defensive cash-flow machines start outperforming, ... 3 Dividend Stocks to Buy Hand Over Fist in July
GLP-1s will fuel the industry’s growth in the coming years if outside forces don’t get in the way.
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock. This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that […]
AbbVie Inc. (NYSE:ABBV) is one of the best dividend aristocrat stocks to buy now. On June 19, AbbVie Inc. (NYSE:ABBV) delivered topline Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress. The results from the Phase 3 CLL14 trial affirm venetoclax’s enduring safety and efficacy in untreated chronic […]
JNJ's Q2 Innovative Medicine results face scrutiny as Stelara biosimilar pressure offsets growth from key blockbusters and newer therapies ahead of earnings.
The iShares MSCI USA Momentum Factor ETF (NYSEARCA:MTUM) has run hard this year, climbing 30% year to date and 38% over the past 12 months to roughly $326. Headline numbers, though, mask a violent rotation inside MTUM’s portfolio. The AI/cloud mega-caps that powered the momentum trade through 2025 have stumbled, while one AI-memory name has ... MTUM Investors: Watch Micron’s Weight at the November Reconstitution
Galderma shares fell after the Swiss skincare specialist failed to obtain approval from the U.S. Food and Drug Administration for its latest product to rival AbbVie’s Botox for the second time. Shares in Galderma were down 5.6% in European morning trading Wednesday, leaving the stock up 7% since the start of the year. The company said it received a complete response letter from the FDA declining its application for the product—marketed in some countries as Relfydess and also known as relabotulinumtoxinA—with comments related to observations during an inspection of the company’s manufacturing site and its analytical method optimization.
AbbVie knows how to plan ahead.
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9%
ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
A bipartisan House committee wants details on hundreds of clinical studies conducted at Chinese military facilities and in Xinjiang
AbbVie (ABBV) and Merck (MRK) are facing investigations by the China Select Committee of the US Hous
June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according to letters seen by Reuters.
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
AbbVie Inc. (NYSE:ABBV) will trade ex-dividend on July 15, putting it among the 10 Best July Dividend Stocks to Buy. On June 27, AbbVie Inc. (NYSE:ABBV) said the Food and Drug Administration approved Skyrizi for pediatric patients with psoriasis. The company said Skyrizi, or risankizumab-rzaa, can now be used in patients aged six years and […]
AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.
If you are trying to figure out whether AbbVie stock still offers value after its recent performance, starting with a clear view of price versus fundamentals is essential. AbbVie has recently traded at US$253.35, with returns of 10.1% over 7 days, 16.4% over 30 days, 10.5% year to date, 40.9% over 1 year, 109.0% over 3 years and 165.3% over 5 years, which has naturally focused attention on whether the current price fairly reflects the business. Recent headlines have focused on AbbVie’s...
AbbVie (NYSE:ABBV) received positive opinions from the European Medicines Agency's CHMP for RINVOQ in severe alopecia areata and non-segmental vitiligo. If approved, RINVOQ could become the first systemic therapy for non-segmental vitiligo in Europe. The new indications target areas with high unmet medical need in dermatology and immunology. AbbVie has been active across immunology, gastroenterology and virology, and RINVOQ is already a core asset in its portfolio. These fresh CHMP...
In the past five years, this top healthcare stock has risen by close to 130%.
AbbVie wins positive CHMP opinions for Rinvoq in severe alopecia areata and non-segmental vitiligo, with EU decisions expected in the coming months.
SYRE has surged on pipeline progress and a strong cash position, but with no product revenue and key trial data still ahead, is the risk already priced in?
SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.